StockData
JAGXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Jaguar Health, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$2.82−0.71 (-20.00%)

Close on Oct 19, 2026

Market cap
$2.28M
P/E (TTM)
–
Dividend yield
–

Jaguar Health, Inc. revenue by segment

By business segment

RevenueQ2 26Q1 26Q4 25Q3 25Q2 25Q1 25Q4 24Q3 24Q2 24Q1 24Q4 23Q3 23% of revenueYoY
Human Health$1.18M$19.93M$3.15M$3.01M$2.86M$2.14M$3.42M$3.01M$2.64M$2.30M$2.25M$2.78M95.9%-59.0%
Animal Health$50.00K$345.00K$83.00K$78.00K$116.00K$76.00K$89.00K$94.00K$84.00K$48.00K$47.00K$31.00K4.1%-56.9%

By product or service

RevenueQ2 26Q1 26Q4 25Q3 25Q2 25Q1 25Q4 24Q3 24Q2 24Q1 24Q4 23Q3 23% of revenueYoY
Mytesi$1.20M$918.00K$3.00M$3.00M$2.80M$2.10M$3.30M$3.00M$2.70M$2.30M$2.30M$2.80M98.0%-57.1%
Product revenue, net$1.18M$1.20M$3.19M$3.04M$2.94M$2.17M$3.47M$3.07M$2.68M$2.35M$2.30M$2.81M96.5%-59.7%
License$43.00K$19.04M$44.00K$42.00K$43.00K$43.00K$44.00K$42.00K$43.00K–––3.5%0.0%
Neonorm$7.00K$7.00K$1.00K$4.00K$14.00K$16.00K$1.00K$4.00K$15.00K$9.00K$7.00K$7.00K0.6%-50.0%
Canalevia-CA1$0$270.00K$40.00K$32.00K$60.00K$17.00K$46.00K$49.00K$26.00K$40.00K$39.00K$24.00K0.0%-100.0%
Grant revenue$0$25.00K––––––––––0.0%–

By region

From the segment and revenue-disaggregation notes of Jaguar Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.